Join
Live feed
·
PRReleasevia Quantisnow
AstraZeneca PLC logo

Baxdrostat met the primary and all secondary endpoints in BaxHTN Phase III trial in patients with uncontrolled or treatment resistant hypertension

ByQuantisnow·Wall Street's wire, on your screen.
AZN· AstraZeneca PLC
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track AZN (AstraZeneca PLC) and more on Quantisnow.